THIRD HARMONIC BIO INC (THRD) Stock Price, Quote, News and Overview
NASDAQ:THRD - Nasdaq - US88427A1079 - Common Stock - Currency: USD
THRD Quote, Performance and Key Statistics
5.16
+0.01 (+0.19%)
The current stock price of THRD is 5.16 USD. In the past month the price increased by 42.54%. In the past year, price decreased by -52.35%.
THRD Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 63.66 | 784.50B | ||
| JNJ | JOHNSON & JOHNSON | 15.7 | 380.15B | ||
| NVO | NOVO-NORDISK A/S-SPONS ADR | 17.37 | 265.94B | ||
| NVS | NOVARTIS AG-SPONSORED ADR | 14.03 | 220.04B | ||
| AZN | ASTRAZENECA PLC-SPONS ADR | 16.35 | 210.42B | ||
| MRK | MERCK & CO. INC. | 10.34 | 198.72B | ||
| PFE | PFIZER INC | 7.24 | 127.78B | ||
| SNY | SANOFI-ADR | 11.63 | 126.93B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 43.7 | 101.37B | ||
| GSK | GSK PLC-SPON ADR | 8.46 | 74.22B | ||
| ZTS | ZOETIS INC | 25.34 | 66.90B | ||
| TAK | TAKEDA PHARMACEUTIC-SP ADR | 33.33 | 48.25B |
Related stock screener links
About THRD
Company Profile
Third Harmonic Bio, Inc. develops pharmaceutical products for the treatment of allergic and immune diseases and disorders. The company is headquartered in San Francisco, California and currently employs 51 full-time employees. The company went IPO on 2022-09-15. The firm is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. The company is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The firm is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.
Company Info
THIRD HARMONIC BIO INC
1700 Montgomery Street, Suite 210
San Francisco CALIFORNIA US
Employees: 42
Company Website: https://thirdharmonicbio.com/
Investor Relations: https://ir.thirdharmonicbio.com/
Phone: 12097272457
THIRD HARMONIC BIO INC / THRD FAQ
What is the stock price of THIRD HARMONIC BIO INC today?
The current stock price of THRD is 5.16 USD. The price increased by 0.19% in the last trading session.
What is the ticker symbol for THIRD HARMONIC BIO INC stock?
The exchange symbol of THIRD HARMONIC BIO INC is THRD and it is listed on the Nasdaq exchange.
On which exchange is THRD stock listed?
THRD stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for THIRD HARMONIC BIO INC stock?
11 analysts have analysed THRD and the average price target is 4.72 USD. This implies a price decrease of -8.58% is expected in the next year compared to the current price of 5.16. Check the THIRD HARMONIC BIO INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is THIRD HARMONIC BIO INC worth?
THIRD HARMONIC BIO INC (THRD) has a market capitalization of 232.72M USD. This makes THRD a Micro Cap stock.
How many employees does THIRD HARMONIC BIO INC have?
THIRD HARMONIC BIO INC (THRD) currently has 42 employees.
What are the support and resistance levels for THIRD HARMONIC BIO INC (THRD) stock?
THIRD HARMONIC BIO INC (THRD) has a support level at 3.42 and a resistance level at 5.17. Check the full technical report for a detailed analysis of THRD support and resistance levels.
Should I buy THIRD HARMONIC BIO INC (THRD) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of THRD, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of THRD, evaluating the profitability, health, valuation and growth aspects
- THIRD HARMONIC BIO INC (THRD) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- THIRD HARMONIC BIO INC (THRD) Sales and EPS estimates to see what analysts future expectations are.
- THIRD HARMONIC BIO INC (THRD) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- THIRD HARMONIC BIO INC (THRD) Insider and Institutional Ownership to learn about the owners and their transactions.
- THIRD HARMONIC BIO INC (THRD) Stock Chart to make your own analysis
- THIRD HARMONIC BIO INC (THRD) Latest news and press-releases to stay up to date.
Does THIRD HARMONIC BIO INC (THRD) stock pay dividends?
THRD does not pay a dividend.
When does THIRD HARMONIC BIO INC (THRD) report earnings?
THIRD HARMONIC BIO INC (THRD) will report earnings on 2025-05-08.
What is the Price/Earnings (PE) ratio of THIRD HARMONIC BIO INC (THRD)?
THIRD HARMONIC BIO INC (THRD) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.27).
What is the Short Interest ratio of THIRD HARMONIC BIO INC (THRD) stock?
The outstanding short interest for THIRD HARMONIC BIO INC (THRD) is 4.61% of its float. Check the ownership tab for more information on the THRD short interest.
THRD Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to THRD. When comparing the yearly performance of all stocks, THRD is a bad performer in the overall market: 80.94% of all stocks are doing better.
THRD Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to THRD. No worries on liquidiy or solvency for THRD as it has an excellent financial health rating, but there are worries on the profitability.
THRD Financial Highlights
Over the last trailing twelve months THRD reported a non-GAAP Earnings per Share(EPS) of -1.27. The EPS decreased by -33.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -15.43% | ||
| ROE | -15.95% | ||
| Debt/Equity | 0 |
THRD Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 75% to THRD. The Buy consensus is the average rating of analysts ratings from 11 analysts.